◈ Nootpedia
Compact view
Research pass: medium Peptide · Intranasal SKIP-FOR-NOW LOW

Synapsin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW LOW

Cerebrolysin already owns Dylan's neuroprotection lane with multi-decade RCT data; Synapsin's combined-blend evidence is laboratory-only with zero published human RCTs on the formulation — adding it on top of Cerebrolysin is mechanism-stacking without evidence. Confidence is LOW because the underlying Rg3 + NAD+-precursor mechanisms are individually plausible (TBI rodent data is real), Synapsin-specific evidence might emerge, and it could become a reasonable Cerebrolysin alternative if EU sourcing breaks. Would re-evaluate if: (a) any human RCT on the compounded blend reads out positive, (b) Cerebrolysin sourcing fails and Dylan needs an at-home, needle-free neuroprotection proxy, or (c) Dylan develops needle aversion that compromises Cerebrolysin adherence.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20–30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW LOW

    Cerebrolysin owns the neuroprotection lane with vastly more evidence; Synapsin would be redundant mechanism-stacking without RCT support. Reconsider only if Cerebrolysin sourcing fails or needle aversion emerges.

  • 30–50, executive maintenance
    OPTIONAL-ADD

    if budget tolerant — convenient at-home, needle-free option for someone unwilling to go IM with Cerebrolysin. Still LOW confidence on outcome.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    population most likely to actually feel the anti-neuroinflammatory mechanism (because they have more inflammation to dampen). Still no RCT evidence.

  • Anxiety-prone
    SKIP

    no anxiolytic mechanism; Selank or L-theanine are better-evidenced.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Cerebrolysin still owns this lane; Synapsin is needle-free convenience without the evidence.

  • Sleep-disordered
    AVOID

    B12-containing variants late in day; otherwise no direct sleep mechanism either way.

  • Recovery-focused (post-injury, post-illness, post-COVID)
    OPTIONAL-ADD

    this is actually Synapsin's strongest empirical (uncontrolled clinical-experience) niche. Long-COVID brain fog clinics use it adjunctively. Still no controlled trials.

  • Strength/anabolic-focused
    SKIP

    no mechanism for muscle/anabolic support; orthogonal to that goal.

▸ Subjective experience (deep)

Highly variable per user reports.

  • Onset: minutes to ~30 min if anything is felt.
  • Peak: subtle — nothing like a stimulant or even a peptide like Selank.
  • Common reports: mild clarity, mild "fog lift," reduction in head pressure / inflammation feel.
  • Common non-reports: a substantial fraction of users (probably the majority of healthy young adults) report nothing perceptible. Synapsin's main value-prop in clinical settings is downstream (post-concussion, chronic fatigue, long COVID), not acute cognitive performance.
  • B12-containing variants can produce stimulation / sleep disruption (intranasal methyl-B12 is itself BBB-active and can be activating). Users report switching to "Synapsin base" without B12 to avoid sleep effects.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: unknown — no formal data.
  • Recommended cycle: pharmacy guidance varies; many recommend continuous daily use, some suggest 5-on/2-off.
  • Reset protocol: not characterized.
▸ Stacking deep dive

Synergistic with

  • cerebrolysin — overlapping neuroprotection thesis. Theoretical synergy (Cerebrolysin = neurotrophic mimetic; Synapsin = microglial + NAD+) but massive evidence asymmetry means there's no rational case for adding Synapsin on top of Cerebrolysin given Dylan's profile and budget. If anything, Cerebrolysin makes Synapsin redundant.
  • alcar — both mitochondrial-leaning. ALCAR is already in V5 plan; combining with intranasal NR-containing Synapsin would over-saturate the NAD+/mitochondrial space without evidence.
  • semax / n-acetyl-semax-amidate — same delivery route (intranasal nose-to-brain) but different mechanism (BDNF mimetic vs anti-inflammatory). Class-mate compatibility, though combining 2–3 nasal sprays adds nasal-irritation burden.
  • nad-plus family compounds — same NAD+ angle as NR component; redundant.

Avoid stacking with

  • No known direct contraindications. Generic caution: not stacking with active intranasal infections / sinusitis.

Neutral / safe co-administration

  • Modafinil, bromantane, magnesium, omega-3s, Dylan's V4 oral stack — all unrelated mechanisms.
▸ Drug interactions deep dive
  • Ginseng class theoretically interacts with warfarin (anticoagulant effect), MAOIs, hypoglycemic agents — but at intranasal microgram doses, systemic exposure is too low to be clinically meaningful. None reported.
  • NR has no significant CYP interactions documented.
  • B12 / methylcobalamin (if included): no major interactions; some users find it activating.
▸ Pharmacogenomics
  • MTHFR variants (C677T, A1298C) — relevant if methyl-folate / methylcobalamin variant is chosen; methylated B-vitamin variants are preferred for MTHFR PMs. Dylan's 23andMe results (~June 2026) will inform.
  • NRK1/NRK2 — enzymes that phosphorylate NR to NMN; polymorphisms theoretically affect NR response, but not characterized clinically.
  • No Rg3-specific pharmacogenomics established.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (telehealth + 503A compounder) TC Compounding (NJ), PD Labs, Fusion Specialty, Wells Pharmacy, EllieMD, Strive, ScriptWorks $80–200/mo for ~30 mL bottle Medium — pharmacy-dependent; refrigerate Most common path; refrigerate after opening; ~30-day beyond-use date
Telehealth-bundled EllieMD, beyondMD, teamwellcore (~$199 starter) $150–250/mo bundled Medium Often packaged with consult fee
OTC / non-compounded N/A — — Not available OTC in US
Russian/Indian gray market N/A — — Not produced in those markets; this is a US-compounding-pharmacy product

No Indian-pharmacy / Russian-vendor path — unlike modafinil or Russian peptides, Synapsin is a US-compounding-pharmacy product. If Dylan ever deployed it, it would be via US Rx telehealth.

▸ Biomarkers to track (deep)
  • Baseline (before starting): hsCRP, IL-6 (neuroinflammation proxies); NfL + GFAP if accessible (concussion biomarkers — same panel relevant for Cerebrolysin); cognitive baseline (CNS Vital Signs / Cambridge Brain Sciences).
  • During use: repeat cognitive battery at 6–8 weeks; subjective brain-fog VAS daily.
  • Post-cycle: repeat hsCRP / IL-6 if cycled. Realistically not enough signal-to-noise to detect change in healthy 20yo without baseline inflammation.
▸ Controversies / open debates Live debate
  • Patent / trademark vs evidence asymmetry: Synapsin is patent-pending and trademarked, marketed by dozens of compounding pharmacies, with zero published RCTs. This is a recurring pattern in the compounded-intranasal space (cf. Semax in Russia has Russian trial data; Synapsin has none).
  • Component-stacking fallacy: the marketing case rests on adding individual mechanisms (Rg3 anti-inflammatory + NR mitochondrial), but combining mechanisms doesn't automatically produce additive clinical effect. This is exactly why Cerebrolysin's track record matters — it has clinical outcome data, not just mechanism.
  • Intranasal dose vs effective rodent dose: rodent Rg3 efficacy is at 20–30 mg/kg systemic. Intranasal Synapsin delivers microgram quantities. Even with nose-to-brain advantage, the brain concentration achieved is uncertain. This is the biggest mechanistic question mark.
  • Cerebrolysin vs Synapsin for the same use case: straightforward — Cerebrolysin has multi-decade RCT data, Synapsin has none. The only argument for Synapsin is convenience (no needle, at-home, no cycling-around-IM-injection). If that's the dispositive factor, Synapsin is the answer; otherwise Cerebrolysin wins on evidence by a wide margin.
  • "Combined natural compound" framing: "natural" is a marketing tell, not an evidence argument. Both Rg3 (extracted, refined ginsenoside) and NR (synthetic vitamin) are far from their natural-source forms by the time they're in a nasal spray.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW LOW. Cerebrolysin owns the neuroprotection lane for Dylan with vastly more evidence; Synapsin's mechanism is plausible but Synapsin-specific human RCT evidence is zero. Pencil in as a contingency only if Cerebrolysin sourcing or compliance fails.
▸ Open questions / gaps Open
  • Actual brain concentration of Rg3 achieved via intranasal microgram dosing in humans (uncharacterized).
  • Whether intranasal NR raises brain NAD+ at a meaningful rate (uncharacterized).
  • Whether the M1→M2 microglial shift seen in rodents at 20–30 mg/kg systemic is reproduced in humans at intranasal microgram doses (likely no, but undefined).
  • Whether long-term daily intranasal use has any unforeseen toxicity (no signal, but no data either).
  • Whether a true Synapsin RCT will ever be funded — compounded-product economics work against it (no patent enforcement on a generic blend → no funder).
  • Where Synapsin sits relative to Cerebrolysin in patients who fail one or the other (untested head-to-head).
▸ Sources (full, with our context)
Back to compact view